New Urine Test Predicts Bladder Cancer Recurrence

the MPR take:

A DNA methylation marker test has been shown to accurately predict tumor recurrence in patients with non-muscle-invasive bladder cancer (NMIBC) with high specificity and sensitivity. Previously utilized markers were more sensitive than standard monitoring methods like cytology and cystoscopy, but are more costly with less specificity. The new marker test measures 3 DNA methylation markers and detected tumor recurrence with high sensitivity and specificity (80% and 97% respectively) vs. 35 and 15% respectively for standard monitoring methods. Due to the high rates of recurrence with NMIBC, researchers hope to identify recurrence prior to the appearance of symptoms and the spread of the cancer.